1. Post marketing clinical trial results will be the boom/bust IMO as the design (by TEVA) will no doubt address every question concerned FDA panel members had.
2. Quarterly earnings reports will show how effective TEVA and Grupo Ferrer are at injecting Adisave into the market, as well as how Alexza management is handling its new money.
3. Guidance reports will tell us how the market is receiving the Adusave and what to expect going forward as well as how much research spending to expect, future NDA catalysts for new products, etc.
Until these next catalysts, barring unforeseen disasters (harm to patients, deaths, manufacturing failures, quality issues) everything else is market manipulation or rumor mongering. This innovative drug delivery system has a long future and promises great returns to the patient disciplined stock holder, IMHO.
To the traders looking to make fast money, this is not your father's biotech company - no big moves up or down are going to be seen here (IMHO of course).